<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126176">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050074</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2013-010</org_study_id>
    <nct_id>NCT02050074</nct_id>
  </id_info>
  <brief_title>The Role of Metformin and Colesevelam in Human GLP-1 Secretion</brief_title>
  <acronym>ColMetInc</acronym>
  <official_title>The Role of Metformin and Colesevelam in Human GLP-1 Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <authority>Denmark: De Videnskabsetiske Komiteer of the Capital Region</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary hypothesis is that bile acid sequestrant colesevelam and the antidiabetic drug
      metformin potentiates the secretion of the gut hormone glucagon-like peptide 1 (GLP-1).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in the gut hormone glucagon-like peptide 1  (GLP-1)</measure>
    <time_frame>0-240 min</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Colesevelam + exendin (9-39)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + exendin (9-39)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + + exendin (9-39)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_label>Colesevelam + exendin (9-39)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Metformin + exendin (9-39)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo + + exendin (9-39)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal hemoglobin

          -  BMI &gt; 23kg/m2

          -  HbA1c &lt;9 %

          -  Informed concent

        Exclusion Criteria:

          -  Liver disease ( aspartate aminotransferase/alanine aminotransferase &gt;2 × reference
             value)

          -  Chronic intestinal disease

          -  History of liver and / or gallbladder disease

          -  Nephropathy (se-creatinine &gt;110 µM and / or albuminuria)

          -  Insulin or GLP-1-based antidiabetic treatment

          -  History of cholecystectomy or surgical resection of bowel segment

          -  BMI &lt;23kg/m2 or BMI &gt;35 kg/m2

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diabetes Research Division, Department of Medicine, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Hansen, Dr.</last_name>
      <phone>+45 3977 2691</phone>
      <email>morten.hansen.02@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Morten Hansen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hansen</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Colesevelam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
